Through comprehensive analyses, including stratification analysis, combined risk genotype analysis, eQTL analysis, survival analysis and clinical correlation analysis, our findings highlight TRDMT1 as a potential marker for neuroblastoma risk assessment and a therapeutic target. Here, TRDMT1 is linked to neuroblastoma.